Why Psilocybin Doesn't Cause SSRI-Style Emotional Blunting

Psilocybin vs. SSRIs

57%

Psilocybin achieved 57% remission vs. 28% with escitalopram in the 2021 Imperial College head-to-head trial — and a 2025 brain imaging analysis of the same participants found psilocybin produced these results without reducing emotional brain responses.

Carhart-Harris et al., New England Journal of Medicine, 2021

28%

remission rate with escitalopram in the same trial, vs. 57% with psilocybin

2025

year of first brain imaging evidence on emotional processing differences (Wall et al., AJP)

6 months

timepoint when psilocybin's advantage in psychological connectedness grew stronger (Erritzoe 2024)

Carhart-Harris et al., New England Journal of Medicine, 2021

View as image ↗

Emotional blunting is among the most commonly reported complaints from people on long-term antidepressants. Not depression itself — but a muted quality to emotional experience that makes life feel filtered. Joy is dimmer. Music doesn't land the same way. Events that should feel significant don't. Researchers call it emotional blunting, and surveys find it affects a substantial proportion of people on serotonin reuptake inhibitors, often enough that patients stop their medication despite clinical improvement in depressive symptoms.

For years, clinicians had patient reports but limited biological evidence for what was happening at the brain level. In 2025, a brain imaging study provided that evidence directly. Researchers at Imperial College London analyzed fMRI data from participants in the landmark trial that first compared psilocybin against an SSRI for depression. What they found was specific: escitalopram reduced brain responses to emotional stimuli across multiple cortical regions, including the amygdala (the brain's primary threat and salience detector). Psilocybin therapy showed no such reduction. If anything, psilocybin participants showed slight increases in brain responses to neutral faces.

This article covers that neuroimaging evidence, its mechanistic explanation, and how it fits with the clinical outcome data from the 2021 trial and its 6-month follow-up. For a broader overview of the evidence on psilocybin for major depression, including the full head-to-head trial results, see the pillar article.

What Emotional Blunting Is and Why It Complicates Antidepressant Treatment

Emotional blunting in the context of antidepressant treatment refers to reduced intensity and range of emotional experience that occurs as a side effect of the medication rather than as a symptom of the illness being treated. The distinction matters because it can appear even as depressive symptoms improve — the patient's score on a depression questionnaire goes down, but they describe feeling cut off from their emotional life.

The subjective experience varies. Some people describe it as feeling like they're watching life from behind glass. Others notice that events that should feel significant — a milestone, a piece of music, a conversation with someone they love — produce a blunted version of the response they'd expect. Positive emotions are often affected more than negative ones, which creates a paradox: the treatment reduces suffering but also reduces some of what makes life feel worth living.

This is distinct from the emotional numbing that depression itself causes. Depression-related numbing is a symptom of the illness. SSRI-related emotional blunting is a pharmacological side effect that can persist even in patients who have recovered from the depressive episode. For a significant number of patients, this side effect is the primary reason they stop taking antidepressants.

The emotional blunting phenomenon has been documented in patient surveys for decades, but the neurobiological mechanism — what is actually happening in the brain — was not demonstrated in imaging data until the 2025 Wall et al. study.

What the 2025 Brain Scans Found: Escitalopram Dulled Emotional Responses. Psilocybin Didn't.

Wall and colleagues at Imperial College London published their neuroimaging analysis in the American Journal of Psychiatry in 2025.^[1] The study used fMRI data collected from a subset of participants in the original Carhart-Harris 2021 trial — the first randomized head-to-head comparison of psilocybin and an SSRI for depression.

While in the scanner, participants viewed images of faces displaying different emotions: happy expressions, fearful expressions, and neutral expressions. Emotional brain responses were measured as patterns of activation in regions involved in processing emotionally significant stimuli, with the amygdala as a key region of interest.

The amygdala's job is not specifically to process negative emotions — it responds to any stimulus that is emotionally salient, positive or negative. A reduced amygdala response to emotional faces is not the same as reduced anxiety; it's reduced sensitivity to emotional significance broadly.

In the escitalopram group, brain responses to emotional faces decreased across multiple cortical regions including the amygdala — for happy faces, for fearful faces, and for neutral faces. This pattern is consistent with what patients describe as emotional blunting: a globally reduced sensitivity to emotional stimuli, not selective suppression of negative feelings.

In the psilocybin group, this pattern was not observed. Psilocybin participants maintained brain responses to emotional faces, and showed slight increases in response to neutral faces. Two treatments that achieved comparable results on the trial's primary depression scale — with psilocybin actually outperforming escitalopram on remission and response rates — produced meaningfully different patterns of brain activation when emotional stimuli were involved.

This is not the same as saying psilocybin enhances emotional intensity in a way that could be problematic. The finding is the absence of the blunting effect, not the presence of an amplification effect beyond normal range.

For a deeper dive into what psilocybin does to emotional processing circuits more broadly, including what fMRI data shows about the mechanisms involved, see psilocybin and emotional processing: the opposite of blunting.

The Mechanism: Why SSRIs Produce This Effect and Psilocybin Doesn't

The difference in brain imaging patterns has a mechanistic explanation grounded in how each treatment works pharmacologically.

SSRIs work by blocking the serotonin transporter, the molecular pump that removes serotonin from the space between nerve cells after a signal is sent. Blocking this pump raises serotonin levels in the synapse. Over weeks and months of daily use, the brain responds to persistently elevated serotonin by reducing the sensitivity of serotonin receptors across multiple receptor types — a process called downregulation. This compensatory adjustment happens broadly, affecting the serotonergic circuits that regulate emotional responses, not just those specifically involved in anxiety or depressive rumination. The result is a kind of global lowering of serotonergic signal intensity — which reduces pathological anxiety and negative thinking, but can also reduce the emotional salience of positive experiences.

Psilocybin works through a different mechanism. Rather than blocking reuptake and chronically raising serotonin levels, psilocybin directly activates a specific type of serotonin receptor — the 5-HT2A receptor — during an acute session lasting six to eight hours. After the session, psilocybin is metabolized and eliminated. The brain is not exposed to chronically elevated serotonin levels. The compensatory receptor downregulation that SSRIs produce does not occur in the same way.

This mechanistic difference predicts different outcomes on emotional processing, and the Wall 2025 imaging data is consistent with that prediction. The SSRI-treated brain, with its broadly reduced serotonergic sensitivity after weeks of treatment, shows dampened responses to emotional stimuli. The psilocybin-treated brain, which experienced a single acute 5-HT2A activation rather than weeks of elevated synaptic serotonin, does not show this pattern.

Both Reduce Negative Thinking, But Through Different Pathways

The 2025 Martens et al. secondary analysis from the same trial adds an important dimension to the emotional processing picture.^[2]

Negative affective bias is the tendency to interpret ambiguous or neutral stimuli as threatening or negative. Someone with depression looking at a face with a neutral expression is more likely to read it as disapproving or hostile. Antidepressants are thought to work in part by reducing this bias — helping patients interpret the world in a less threat-saturated way.

Martens found that both psilocybin and escitalopram reduced negative affective bias to comparable levels. Both treatments produced healthier, less threat-focused interpretations of ambiguous emotional stimuli. On this specific dimension, the treatments were equivalent.

What differed was how each treatment achieved this reduction. Escitalopram reduced negative affective bias by broadly decreasing emotional responding — turning down the overall signal volume across emotional stimuli, both negative and positive. Psilocybin reduced negative affective bias while maintaining overall emotional responsiveness.

In practical terms: both treatments made patients less likely to interpret ambiguous situations as threatening. Psilocybin did so without also making patients less likely to feel moved by something genuinely positive.

The Wall 2025 imaging data shows this distinction at the neural level. Escitalopram's reduction in amygdala response was global — affecting happy faces, fearful faces, and neutral faces alike. Psilocybin's absence of this global reduction is the neuroimaging correlate of what Martens found behaviorally: maintained emotional range alongside reduced negativity bias.

At 6 Months, the Clinical Data Told the Same Story

The 2021 Carhart-Harris trial followed patients for six weeks after treatment, during which psilocybin outperformed escitalopram on every secondary outcome: 57% vs 28% remission, 70% vs 48% response, and greater improvements in well-being, emotional functioning, and psychological connectedness.^[3]

Erritzoe and colleagues published a 6-month observational follow-up of the same participants in eClinicalMedicine, a Lancet journal, in 2024.^[4] Both treatment groups maintained their improvements at 6 months. But the advantage for psilocybin on quality-of-life outcomes had grown larger over time, not smaller.

At 6 months, psilocybin participants showed greater improvements in meaning in life, psychological connectedness, and psychosocial functioning compared to the escitalopram group. These are the dimensions of experience most dependent on emotional range: feeling connected to other people, finding situations meaningful, being able to engage fully with one's own life.

The pattern is consistent with what the Wall 2025 imaging data would predict. A treatment that maintains emotional responsiveness should produce better outcomes over time on the dimensions of life that require emotional engagement. A treatment that broadly reduces emotional sensitivity may achieve short-term symptom reduction but at the cost of the very experiences that make recovery feel meaningful.

Psilocybin is metabolized within 24 hours of a session. The 6-month data reflects changes that outlasted the drug's presence in the body by months. Whatever reorganization of emotional processing occurred during the acute psilocybin experience appears to have produced lasting changes in how participants engaged with their emotional lives — changes that SSRIs, taken daily for the full period, did not produce to the same degree.

For a look at what patients report about emotional reconnection after psilocybin, including accounts that parallel what the clinical data shows about emotional range, see psilocybin and emotional reconnection: why patients report feeling again.

What This Means for Patients Weighing Their Options

The four studies — Wall 2025, Martens 2025, Carhart-Harris 2021, and Erritzoe 2024 — build a coherent picture of two treatments with different emotional processing profiles.

SSRIs achieve antidepressant effects through chronic serotonergic modulation. This mechanism reduces pathological anxiety and depressive rumination, but it also reduces emotional responsiveness broadly in a meaningful proportion of users. The brain imaging evidence from 2025 shows this effect directly: reduced amygdala responses to emotional faces in the SSRI group.

Psilocybin achieves antidepressant effects through acute 5-HT2A activation. It does not produce the chronic serotonergic changes that drive receptor desensitization. The brain imaging shows the absence of the blunting effect, and the clinical data at 6 months shows greater improvements in the outcomes that depend on emotional engagement.

For patients who have experienced emotional blunting on antidepressants and are seeking an alternative, the Wall 2025 data provides the most direct neurobiological evidence that psilocybin does not produce the same pattern. For patients wondering whether psilocybin can specifically address anhedonia — the inability to feel pleasure that is both a depression symptom and a known consequence of emotional blunting — see psilocybin and anhedonia: restoring the ability to feel pleasure.

For patients currently on SSRIs who are considering psilocybin therapy, the research on transitioning between these treatments matters. SSRIs attenuate psilocybin's effects in a substantial proportion of cases, and this dampening can persist for up to three months after stopping the SSRI. See switching from SSRIs to psilocybin therapy: what the research shows for the evidence on how to think about this transition.

Psilocybin therapy is not approved for depression in most jurisdictions and is not available outside clinical trials in most places. This analysis reports what the current research shows about mechanistic differences between two treatments — not a recommendation about which treatment any individual should choose.

For a full analysis of the Imperial College head-to-head trial results, including what the primary and secondary outcomes actually showed and why the "no significant difference" headline missed the story, see psilocybin vs. escitalopram: the Imperial College head-to-head trial.

The Bottom Line

Brain imaging evidence published in 2025 (Wall et al., AJP) showed escitalopram reduces brain responses to emotional faces across cortical regions including the amygdala, while psilocybin therapy does not — the first direct neuroimaging evidence of the emotional blunting difference between these treatments. This finding is consistent with the 2021 trial's secondary outcomes (57% vs 28% remission, greater emotional well-being in psilocybin group) and with the 6-month follow-up showing psilocybin's advantage in psychological connectedness and meaning in life grew larger over time. The mechanistic explanation centers on the difference between chronic reuptake blockade (SSRIs) and acute 5-HT2A activation (psilocybin).

Frequently Asked Questions

Does psilocybin cause emotional blunting like SSRIs?

Based on current evidence, psilocybin does not appear to cause the same pattern of emotional blunting seen with SSRIs. A 2025 brain imaging study (Wall et al., AJP) found escitalopram reduced brain responses to emotional faces across regions including the amygdala; psilocybin showed no such reduction. The 2021 head-to-head trial also found greater improvements in emotional functioning and well-being with psilocybin compared to escitalopram.

What is emotional blunting from SSRIs?

Emotional blunting from SSRIs refers to a reduction in the intensity and range of emotional experience that occurs as a side effect of the medication, separate from its antidepressant effects. It can appear even as depressive symptoms improve. People describe it as feeling emotionally muted or watching life from behind glass — with positive emotions often affected more than negative ones. Brain imaging from 2025 (Wall et al.) shows this effect at the neural level as reduced amygdala and cortical responses to emotional stimuli.

Does psilocybin restore emotional feeling?

The clinical data is consistent with this. In the 2021 head-to-head trial, psilocybin participants reported greater improvements in emotional well-being, connectedness, and meaning at 6 weeks, and these advantages were larger at 6 months (Erritzoe et al., 2024). The brain imaging data (Wall 2025) shows psilocybin did not reduce emotional brain responses. Whether these findings represent the restoration of emotional feeling previously blunted by SSRIs versus independent emotional enhancement is not yet separable from the clinical data.

Why do SSRIs cause emotional numbness?

SSRIs work by blocking serotonin reuptake, which chronically raises serotonin levels in brain synapses. Over weeks of treatment, the brain compensates by broadly reducing the sensitivity of serotonin receptors. This desensitization affects emotional processing circuits that normally respond to both positive and negative stimuli, not just the anxiety circuits the treatment targets. The result is a global reduction in emotional sensitivity — not selective suppression of negative feelings — which is what patients describe as emotional numbness or blunting.

Can psilocybin fix SSRI-induced emotional blunting?

The research does not yet directly test this question. The 2021 trial enrolled patients with depression, not patients experiencing SSRI-induced blunting specifically. The Wall 2025 imaging study shows psilocybin therapy doesn't produce emotional blunting, and the 6-month clinical data shows greater emotional connectedness with psilocybin than escitalopram. Whether psilocybin can specifically reverse blunting that SSRIs caused is a question that would require a dedicated study design. Psilocybin therapy is also not available as a treatment in most jurisdictions outside of clinical trials.

What is the difference between how SSRIs and psilocybin affect emotions?

SSRIs block serotonin reuptake chronically, causing broad desensitization of serotonergic circuits including those processing emotional salience — this produces antidepressant effects but can also blunt emotional responsiveness. Psilocybin directly activates the 5-HT2A serotonin receptor acutely during a single session without chronically elevating serotonin. Brain imaging from 2025 shows this difference directly: SSRIs reduced brain responses to emotional faces; psilocybin did not. Both reduced negative affective bias (Martens 2025) — but psilocybin did so while maintaining overall emotional responsiveness.

Sources & References

1. 1. Source details for this reference are not yet available.
2. 2. Source details for this reference are not yet available.
3. 3. Source details for this reference are not yet available.
4. 4. Source details for this reference are not yet available.